Oakbrook Investments LLC cut its position in Boston Scientific Co. (NYSE:BSX) by 2.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 79,425 shares of the medical equipment provider’s stock after selling 1,900 shares during the quarter. Oakbrook Investments LLC’s holdings in Boston Scientific were worth $3,058,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in BSX. Baird Financial Group Inc. boosted its stake in Boston Scientific by 28.6% during the 1st quarter. Baird Financial Group Inc. now owns 19,702 shares of the medical equipment provider’s stock valued at $538,000 after purchasing an additional 4,387 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in Boston Scientific by 2.7% during the 1st quarter. Commonwealth Equity Services LLC now owns 71,279 shares of the medical equipment provider’s stock valued at $1,947,000 after purchasing an additional 1,850 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in Boston Scientific by 10.3% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 41,894 shares of the medical equipment provider’s stock valued at $1,135,000 after purchasing an additional 3,924 shares during the last quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp acquired a new position in Boston Scientific during the 1st quarter valued at about $5,024,000. Finally, Royal Bank of Canada boosted its stake in Boston Scientific by 67.3% during the 1st quarter. Royal Bank of Canada now owns 1,566,013 shares of the medical equipment provider’s stock valued at $42,784,000 after purchasing an additional 630,046 shares during the last quarter. Institutional investors and hedge funds own 91.03% of the company’s stock.

Boston Scientific stock opened at $37.53 on Friday. Boston Scientific Co. has a 52 week low of $24.54 and a 52 week high of $39.44. The company has a current ratio of 0.83, a quick ratio of 0.60 and a debt-to-equity ratio of 0.62. The company has a market cap of $52.55 billion, a price-to-earnings ratio of 29.79, a PEG ratio of 2.64 and a beta of 0.59.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 25th. The medical equipment provider reported $0.41 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.34 by $0.07. Boston Scientific had a net margin of 5.48% and a return on equity of 26.35%. The firm had revenue of $2.49 billion for the quarter, compared to analysts’ expectations of $2.47 billion. During the same quarter last year, the firm earned $0.32 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts expect that Boston Scientific Co. will post 1.39 earnings per share for the current fiscal year.

A number of equities analysts have issued reports on BSX shares. Morgan Stanley lifted their price target on Boston Scientific from $33.00 to $38.00 and gave the company an “overweight” rating in a research note on Thursday, July 26th. Piper Jaffray Companies lifted their price target on Boston Scientific to $38.00 and gave the company an “overweight” rating in a research note on Thursday, July 26th. Jefferies Financial Group reiterated a “hold” rating and set a $34.00 price target on shares of Boston Scientific in a research note on Thursday, July 26th. Stifel Nicolaus reiterated a “buy” rating and set a $37.00 price target on shares of Boston Scientific in a research note on Thursday, July 26th. Finally, Needham & Company LLC reiterated a “strong-buy” rating on shares of Boston Scientific in a research note on Friday, July 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $38.22.

In other Boston Scientific news, EVP David A. Pierce sold 5,000 shares of Boston Scientific stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $38.80, for a total transaction of $194,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP John Bradley Sorenson sold 10,000 shares of Boston Scientific stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $35.86, for a total transaction of $358,600.00. Following the transaction, the senior vice president now directly owns 44,636 shares in the company, valued at approximately $1,600,646.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 295,834 shares of company stock worth $11,038,468. Insiders own 0.73% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Article: Call Option

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.